Changzhou Niujin Shisong Biotechnology Company Ltd. (CNSB) was founded in September 2012 between Dr. Shisong Jiang and Mr. Wenhui Jin. Its main purpose is to develop products and, to further improve the technology, based on Dr. Jiang's Recombinant Overlapping Peptides (ROP) method which he developed from his earlier research in Oxford University. The ROP process was patented under Dr. Jiang and Oxford University, and it was spun-out by the University to become Oxford Vacmedix in September 2012. Oxford Vacmedix is a holding company that owns the world wide right of this platform technology, and CNSB works with Oxford Vacmedix (Hong Kong ), a subsidiary of Oxford Vacmedix, to develop products for 4 indications from this platform technology for the greater China market. The 4 indications are namely; HPV for cervical cancer, Survivin for solid tumors, TB for Tuberculosis and EBV for Nasal-pharyngeal Carcinoma.
江苏快乐十分网址ROP is a process for making multiple long peptides, which has a great potential in producing therapeutic vaccines ( biopharmaceuticals) which could stimulate both CD4 and CD8 responses. This technology could also offer economical and regulatory advantages when compared with synthetic long peptides for the same purpose.
江苏快乐十分网址CNSB has its own research and development laboratory in the Changzhou Biopharmaceutical Incubation Center, and it works closely with leading research institutions in China in different areas of developmental works. For example, with Institute of Biotechnology of Shanghai Academy of Agricultural Sciences in up-stream molecular biology of ROP; Institute of Bioengineering of Eastern China University of Science & Technology in fermentation and processing; Shanghai Biomodel Center in animal experiments and, Beijing You An Hospital and Shanghai No.10 People's Hospital in TB diagnostics.
For the last 2 years, CNSB has achieved break-through in the development of HPV and Survivin therapeutic agents, and a diagnostic system for in-vitro assay of TB. The company is now looking for out-licensing or co-development opportunities with Pharmaceutical Corporations or investors for the commercial development of these products.
江苏快乐十分网址For more information, please contact;
Dr. Shisong Jiang, CEO, Changzhou Niujin Shisong Biotechnology.